GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

icotrokinra   Click here for help

GtoPdb Ligand ID: 14181

Synonyms: JNJ-2113 | JNJ-77242113 | JNJ77242113
Immunopharmacology Ligand
Compound class: Peptide
Comment: Icotrokinra (JNJ-77242113) is an oral IL-23 receptor peptide inhibitor (antagonist) [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=CC2=C1NC=C2C[C@H]3C(=O)N[C@@H](CCCCNC(=O)C)C(=O)N[C@H](C(=O)N[C@@H](CC4=CC=C(C=C4)OCCN)C(=O)N[C@@H](CC5=CC6=C(C=CC=C6)C=C5)C(=O)NC7(CCOCC7)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC8=CC=CN=C8)C(=O)N(C)CC(=O)N)C(C)(C)SSC(C)(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N3)NC(=O)C
Isomeric SMILES CC1=C2C(=CC=C1)C(=CN2)C[C@H]3C(=O)N[C@H](C(=O)N[C@@H](C(SSC([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)[C@@H](C)O)CC(=O)N)NC(=O)C)(C)C)(C)C)C(=O)N[C@@H](CC4=CC=C(C=C4)OCCN)C(=O)N[C@@H](CC5=CC6=CC=CC=C6C=C5)C(=O)NC7(CCOCC7)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC8=CN=CC=C8)C(=O)N(C)CC(=O)N)CCCCNC(=O)C
InChI InChI=1S/C90H120N20O22S2/c1-48-16-14-20-59-57(46-97-72(48)59)42-64-79(122)99-60(21-12-13-34-96-50(3)112)77(120)108-75(89(7,8)134-133-88(5,6)74(98-51(4)113)84(127)104-66(44-69(93)115)81(124)107-73(49(2)111)83(126)102-64)85(128)103-62(39-52-23-26-58(27-24-52)132-37-32-91)78(121)100-63(40-53-22-25-55-18-10-11-19-56(55)38-53)82(125)109-90(30-35-131-36-31-90)87(130)106-61(28-29-71(117)118)76(119)101-65(43-68(92)114)80(123)105-67(41-54-17-15-33-95-45-54)86(129)110(9)47-70(94)116/h10-11,14-20,22-27,33,38,45-46,49,60-67,73-75,97,111H,12-13,21,28-32,34-37,39-44,47,91H2,1-9H3,(H2,92,114)(H2,93,115)(H2,94,116)(H,96,112)(H,98,113)(H,99,122)(H,100,121)(H,101,119)(H,102,126)(H,103,128)(H,104,127)(H,105,123)(H,106,130)(H,107,124)(H,108,120)(H,109,125)(H,117,118)/t49-,60+,61+,62+,63+,64+,65+,66+,67+,73+,74-,75-/m1/s1
InChI Key IVFNYXYPMJQSGF-QMRCQSNESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
JNJ-77242113 is being evaluated for safety and efficacy as a therapeutic for inflammatory autoimmune conditions, including psoriasis and ulcerative colitis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05223868 A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis Phase 2 Interventional Janssen Research & Development, LLC 1
NCT06049017 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2 Interventional Janssen Research & Development, LLC
NCT06934226 A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis Phase 3 Interventional Janssen Research & Development, LLC
NCT06878404 A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis Phase 3 Interventional Janssen Research & Development, LLC
NCT06807424 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis Phase 3 Interventional Janssen Research & Development, LLC